Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* male or female subjects who are ≥18 years of age on the day of signing informed consent,~* have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR criteria of RA and ACR functional class I-III,~* have ≥6 swollen joints (from a 66-joint count) and~  ≥8 tender joints (from a 68-joint count) at Screening and at Baseline,~* Screening serum c-reactive protein ≥ 0.7 x upper limit of laboratory normal range (ULN),~* have shown an inadequate response in terms of either lack of efficacy or toxicity to MTX,~* have agreed to be washed out from MTX for a period of at least 4 weeks before or during the Screening period.~Exclusion Criteria:~* current therapy with any non-biological disease modifying anti-rheumatic drug (DMARD), with the exception of antimalarials, which must be at a stable dose for at least 12 weeks prior to Screening,~* current or previous RA treatment with a biologic DMARD, with the exception of biologic DMARDs: administered in a single clinical study setting, and; more than 6 months prior to Screening (12 months for rituximab or other B cell depleting agents), and; where the biologic DMARD was effective, and if discontinued, this should not be due to lack of efficacy,~* previous treatment at any time with a cytotoxic agent, other than MTX, before Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received GLPG0634 matching placebo capsules, orally, once daily (QD) during Weeks 1 to 12 and GLPG0634 100 milligram (mg) QD during Weeks 13 to 24.
- GLPG0634 50 mg QD (Type: EXPERIMENTAL): Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
- GLPG0634 100 mg QD (Type: EXPERIMENTAL): Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
- GLPG0634 200 mg QD (Type: EXPERIMENTAL): Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).